City of Hope | Association Partnerships

Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.

Mayuko Sakae, MD, discusses findings from research presented at the 2024 Multinational Association of Supportive Care in Cancer Annual Meeting on refractory pain in patients who have undergone a bone marrow transplant.

In an interview with Targeted Oncology, Richard Lee, MD, discussed what integrative oncology encompasses and its significance in modern cancer care.

Mayuko Sakae, MD, discussed research on pain management for patients undergoing bone marrow transplants, highlighting the potential buprenorphine shows in offering a valuable alternative to traditional opioids.

Ajaz M. Khan, MD, MBA, CPE, provides his insights into the novel biomarkers and up-front immunotherapies that are changing the landscape of treatment for patients with lung cancer.

The latest research on circulating tumor DNA and circulating tumor cells isolated through liquid biopsies is revolutionizing cancer care by enabling early detection, treatment monitoring, and personalized medicine strategies.

Finly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the background and findings from a study comparing patients who underwent thymectomy and nephrectomy.

Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.

The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.

Regina Barragan-Carrillo, MD, discusses results of a study which sought to assess the association between thymectomy and incidence of renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.

Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.

A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.

Alex Chehrazi-Raffle, MD, discusses findings from a real-world analysis of adjuvant treatment in bladder cancer presented at ASCO GU.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

Regina Barragan-Carrillo, MD, discusses an abstract which evaluated the association between thymectomy and incidence of renal cell carcinoma.

In an interview with Targeted Oncology, Yanghee Woo, MD, discussed some factors to consider when choosing between CROSS and FLOT for gastreoesophageal junction adenocarcinoma treatment.

In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.

A novel CAR T-cell therapy being developed at City of Hope offers a potential new treatment avenue for patients with recurrent glioblastoma and high-grade glioma. 

March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.

In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.

Hedyeh Ebrahimi, MD, discussed a novel approach to targeting metastatic renal cell carcinoma through a microbiome-mediated pathway.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the findings from her analysis of the Language of Respect guidelines adopted by the American Society of Clinical Oncology and how well they are followed in prostate cancer abstracts.